Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O75900

UPID:
MMP23_HUMAN

ALTERNATIVE NAMES:
Femalysin; MIFR-1; Matrix metalloproteinase-21; Matrix metalloproteinase-22

ALTERNATIVE UPACC:
O75900; A2AGN0; A2AGN1; O75894; O75895; Q5QPQ8; Q76P96; Q7LDM6; Q7LDM7; Q9UBR9; Q9UJK8

BACKGROUND:
The protein Matrix metalloproteinase-23, with its aliases Femalysin, MIFR-1, and Matrix metalloproteinases 21 and 22, serves as a protease. It is believed to influence the surface expression of potassium channels through retention in the endoplasmic reticulum, indicating its pivotal role in cellular functionality.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Matrix metalloproteinase-23 opens up avenues for innovative therapeutic approaches. Its critical role in managing potassium channel expression makes it an attractive candidate for the development of novel drug therapies, potentially revolutionizing treatment modalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.